-
Contact the PP Team
Buying shares?
- Thread starter DeadlyVenom
- Start date
VAL Looks like a very positive update on their early stage cancer trials
https://www.investegate.co.uk/valir...nical-development-update/201712120700040239Z/
London, UK., 12 December 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek, the joint venture between ValiRx and Tangent Reprofiling Limited.
Further to the release of pharmacokinetic data from the completed Phase II clinical trial in Tbilisi, Georgia (as announced on 28 September 2017), the Company is pleased to now announce the positive formal data release pertaining to disease impact. The results demonstrate that the VAL401 treatment has a statistically significant improvement in Overall Survival ("OS") for patients with non-small cell lung cancer compared to those receiving no treatment.
The Company is in discussion with a number of large pharmaceutical companies who are looking to fill their pipelines in this therapeutic area.
https://www.investegate.co.uk/valir...nical-development-update/201712120700040239Z/
London, UK., 12 December 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide a positive update on the clinical progress of VAL401, the anti-cancer compound developed by ValiSeek, the joint venture between ValiRx and Tangent Reprofiling Limited.
Further to the release of pharmacokinetic data from the completed Phase II clinical trial in Tbilisi, Georgia (as announced on 28 September 2017), the Company is pleased to now announce the positive formal data release pertaining to disease impact. The results demonstrate that the VAL401 treatment has a statistically significant improvement in Overall Survival ("OS") for patients with non-small cell lung cancer compared to those receiving no treatment.
The Company is in discussion with a number of large pharmaceutical companies who are looking to fill their pipelines in this therapeutic area.
Good update from AXM this morning
Has potential to be a stormer this one
http://www.investegate.co.uk/alexander-mining-plc--axm-/rns/business-update/201712130700021524Z/
Has potential to be a stormer this one
http://www.investegate.co.uk/alexander-mining-plc--axm-/rns/business-update/201712130700021524Z/
GDR GeneDrive
Remodelled for growth - genedrive plc is a commercial-stage company focused on point-of-care/need molecular diagnostics and biomarkers. Its Genedrive® in vitro diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in infectious disease diagnosis. The rapid and accurate analysis of patient samples aids significantly the clinical decision process, with point-of-need testing particularly important in emerging markets. Hepatitis C diagnosis is a multi-million dollar market opportunity, which is well supported by the WHO and other philanthropic organisations.
Please click here for the full report:
http://hardmanandco.com/docs/defaul...-documents/13.12.17-remodelled-for-growth.pdf
Remodelled for growth - genedrive plc is a commercial-stage company focused on point-of-care/need molecular diagnostics and biomarkers. Its Genedrive® in vitro diagnostic testing platform is at the forefront of this technology, offering a rapid, low-cost, simple-to-use device with high sensitivity and specificity in infectious disease diagnosis. The rapid and accurate analysis of patient samples aids significantly the clinical decision process, with point-of-need testing particularly important in emerging markets. Hepatitis C diagnosis is a multi-million dollar market opportunity, which is well supported by the WHO and other philanthropic organisations.
Please click here for the full report:
http://hardmanandco.com/docs/defaul...-documents/13.12.17-remodelled-for-growth.pdf
AOR looks crazy cheap to me
People are chasing 'shells' which are valued more than this Company which actually has potential to be a £50-100m+ company
Aortech (AOR)
sp 22.5p
shares o/s 5.6m
mkt cap £1.2m
AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.
Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.
Financials
Revenue $614k
Profit $55k
Cash $114k
Upside ?
1. Change in licensing strategy
"Our manufacturing licensee, Biomerics concluded a licence for Elast-Eon™ earlier this year together with a long term supply agreement. There are currently a number of companies evaluating Elast-Eon™ which if succesful may lead to other licences. Biomerics adopts a different approach to licensing to that which AorTech has historically pursued. AorTech signed a number of licences with very small/development companies long before products were ready for market launch. As a result, other than annual maintenance fees, the revenues from those licences depended upon future product launches. By contrast, Biomerics is focussed on volume supply and near term success."
2.Additional licensing opportunities
Some historic licences signed by the Company have not generated value for AorTech and have only resulted in the Elast-Eon™ material not being exploited in the field of the licence. An example of this was the licence for breast implants signed in 2011. Since that time, AorTech's technology has not been incorporated into any new device nor generated any revenue for AorTech despite maintaining an IP portfolio in this arena. Your Board still believes there to be substantial benefits in utilising Elast-Eon™ technology in cosmetic and reconstructive surgery and as a result recently terminated this licence in order to pursue other opportunities in the field.
Outlook/Conclusion (from August 15th Final Results RNS)
"A new revenue-generating licence has been signed and enquiries have increased markedly. We have taken back control of our breast implant IP and are actively pursuing opportunities to exploit this alongside our other intellectual property, including heart valves and polymers."
https://www.investegate.co.uk/aortech-inter-plc--aor-/rns/final-results/201708160700030839O/
-------------------------------
Interesting stakebuilding.
Former CEO who resigned in Oct 2016 went above 10% holding in Sept 2017
Litigation
They were suing another former CEO but looks like settlement on that soon. Just drawing a line under it should be positive.
---------------------------------
http://biomerics.com/elast-eon-bringing-quality-value-medical-device-project/
People are chasing 'shells' which are valued more than this Company which actually has potential to be a £50-100m+ company
Aortech (AOR)
sp 22.5p
shares o/s 5.6m
mkt cap £1.2m
AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.
Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.
Financials
Revenue $614k
Profit $55k
Cash $114k
Upside ?
1. Change in licensing strategy
"Our manufacturing licensee, Biomerics concluded a licence for Elast-Eon™ earlier this year together with a long term supply agreement. There are currently a number of companies evaluating Elast-Eon™ which if succesful may lead to other licences. Biomerics adopts a different approach to licensing to that which AorTech has historically pursued. AorTech signed a number of licences with very small/development companies long before products were ready for market launch. As a result, other than annual maintenance fees, the revenues from those licences depended upon future product launches. By contrast, Biomerics is focussed on volume supply and near term success."
2.Additional licensing opportunities
Some historic licences signed by the Company have not generated value for AorTech and have only resulted in the Elast-Eon™ material not being exploited in the field of the licence. An example of this was the licence for breast implants signed in 2011. Since that time, AorTech's technology has not been incorporated into any new device nor generated any revenue for AorTech despite maintaining an IP portfolio in this arena. Your Board still believes there to be substantial benefits in utilising Elast-Eon™ technology in cosmetic and reconstructive surgery and as a result recently terminated this licence in order to pursue other opportunities in the field.
Outlook/Conclusion (from August 15th Final Results RNS)
"A new revenue-generating licence has been signed and enquiries have increased markedly. We have taken back control of our breast implant IP and are actively pursuing opportunities to exploit this alongside our other intellectual property, including heart valves and polymers."
https://www.investegate.co.uk/aortech-inter-plc--aor-/rns/final-results/201708160700030839O/
-------------------------------
Interesting stakebuilding.
Former CEO who resigned in Oct 2016 went above 10% holding in Sept 2017
Litigation
They were suing another former CEO but looks like settlement on that soon. Just drawing a line under it should be positive.
---------------------------------
http://biomerics.com/elast-eon-bringing-quality-value-medical-device-project/
<blockquote class="twitter-video" data-lang="en"><p lang="en" dir="ltr"><a href="https://twitter.com/hashtag/AOR?src=hash&ref_src=twsrc%5Etfw">#AOR</a> AorTech [ SP: 60p Shs: 5.6m Mkt Cap: £3.4m ]<br><br>VIDEO: This is the tech guru behind AorTech products <a href="https://t.co/9W0u0PIQhn">pic.twitter.com/9W0u0PIQhn</a></p>— Stockonomist (@Stockonomist) <a href="https://twitter.com/Stockonomist/status/940241411437449216?ref_src=twsrc%5Etfw">December 11, 2017</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
AOR AorTech
I've rarely seen an RNS this bullish from a Company
"Platform Technology
Elast-Eon™ polymers are now widely accepted as being the most biostable of all polyurethane materials and, as such, are being used in long term implantation. With several million implants and ten years of successful clinical use, AorTech polymers are used in cardiology and urological applications, including pacing leads, cardiac cannulae and coronary artery stents. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, and CE Marks. Elast-Eon™ is approved for long term human implants in all major markets.
The business model has not really changed over the 15 years since AorTech withdrew from medical device manufacturing in Scotland and focused on licensing its polymer technology to medical device companies. AorTech has however simplified its operations by subcontracting polymer manufacture to Biomerics rather than operate its own polymer plant. This change has dramatically improved the fundamental economics of the business and has resulted in long term contractual revenue streams that are secure as long as the licensees continue to market the devices that have been enabled by incorporating into their designs the Elast-Eon™ technology.
Our licensees have generated considerable value by utilising Elast-Eon™. One example of this is a cardiovascular device that differs only from competing devices by having a thin Elast-Eon™ coating. This coating provides the device with superior properties and allows a sales price of many multiples of standard devices. The cost of materials and license fees, however, are less than 5% of the device's sales value.
The value added to licensees is not only greater than licence fees payable, but the value of the licence fees to our customers is significantly more than the market capitalisation of AorTech
A New Chapter
The long-running litigation dispute created a number of uncertainties for AorTech and its shareholders and at the time of announcing results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.
The recent trading results should indicate to shareholders that the business is on a more stable footing and the risk of failure diminished. The cash position improved during the six months to 30 September 2017 and at the end of November 2017 had further increased to $328,000. As a result of the conclusion of the litigation, AorTech will have certain costs to pay and make reimbursements to our insurance provider. However, we anticipate that the net cash position should improve further.
The Board has conducted a thorough review of the Company's IP and where it fits into the medical device market, leading to the conclusion that there are a number of opportunities available to grow AorTech's business. A detailed strategic plan to allow AorTech to commercialise its platform technology is currently being considered and we will report to shareholders when the process is concluded.
We have the opportunity of putting past issues behind us and building on the core IP within the business. As part of this "fresh start", I am delighted to welcome Stockdale Securities as our new Nominated Adviser and broker and look forward to working with them to help AorTech reach its true potential."
I've rarely seen an RNS this bullish from a Company
"Platform Technology
Elast-Eon™ polymers are now widely accepted as being the most biostable of all polyurethane materials and, as such, are being used in long term implantation. With several million implants and ten years of successful clinical use, AorTech polymers are used in cardiology and urological applications, including pacing leads, cardiac cannulae and coronary artery stents. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510ks, and CE Marks. Elast-Eon™ is approved for long term human implants in all major markets.
The business model has not really changed over the 15 years since AorTech withdrew from medical device manufacturing in Scotland and focused on licensing its polymer technology to medical device companies. AorTech has however simplified its operations by subcontracting polymer manufacture to Biomerics rather than operate its own polymer plant. This change has dramatically improved the fundamental economics of the business and has resulted in long term contractual revenue streams that are secure as long as the licensees continue to market the devices that have been enabled by incorporating into their designs the Elast-Eon™ technology.
Our licensees have generated considerable value by utilising Elast-Eon™. One example of this is a cardiovascular device that differs only from competing devices by having a thin Elast-Eon™ coating. This coating provides the device with superior properties and allows a sales price of many multiples of standard devices. The cost of materials and license fees, however, are less than 5% of the device's sales value.
The value added to licensees is not only greater than licence fees payable, but the value of the licence fees to our customers is significantly more than the market capitalisation of AorTech
A New Chapter
The long-running litigation dispute created a number of uncertainties for AorTech and its shareholders and at the time of announcing results for the year to 31 March 2017 the share price was implying that AorTech was likely to fail.
The recent trading results should indicate to shareholders that the business is on a more stable footing and the risk of failure diminished. The cash position improved during the six months to 30 September 2017 and at the end of November 2017 had further increased to $328,000. As a result of the conclusion of the litigation, AorTech will have certain costs to pay and make reimbursements to our insurance provider. However, we anticipate that the net cash position should improve further.
The Board has conducted a thorough review of the Company's IP and where it fits into the medical device market, leading to the conclusion that there are a number of opportunities available to grow AorTech's business. A detailed strategic plan to allow AorTech to commercialise its platform technology is currently being considered and we will report to shareholders when the process is concluded.
We have the opportunity of putting past issues behind us and building on the core IP within the business. As part of this "fresh start", I am delighted to welcome Stockdale Securities as our new Nominated Adviser and broker and look forward to working with them to help AorTech reach its true potential."
and this was from earlier Final Results statement
"A new revenue-generating licence has been signed and enquiries have increased markedly. We have taken back control of our breast implant IP and are actively pursuing opportunities to exploit this alongside our other intellectual property, including heart valves and polymers."
Crazy this company valued at less than £2m
"A new revenue-generating licence has been signed and enquiries have increased markedly. We have taken back control of our breast implant IP and are actively pursuing opportunities to exploit this alongside our other intellectual property, including heart valves and polymers."
Crazy this company valued at less than £2m
Last edited:
RRR after big initial move 0.40 to 0.80 consolidating now at around 0.60. Still a bit more sideways working needed but then expect a wave 2 and wave 3 move higher.
here's chart
great set up
negating and reversing a Death Cross with a Golden Cross in coming weeks will be further great technical signal
some good assets and potential catalysts upcoming
could/should trade at c.2p with potential for 4-8p possible
Last edited:
AOR
parsons4 16 Dec '17 - 13:21 - 3431 of 3432
I am relatively new to this one and bought my first holding a few days ago. I think it was TS that mentioned it on the VRS site !! thanks for that. It seems that the company have good products but has been terribly run by previous management for many years. It seems that if there was anything to go wrong it did !!!! But the potential if they now get it right considering the market cap is huge. Have we now got the right management and is Bill Brown any good considering that he has been there for years ?
The Stigologist 16 Dec '17 - 13:58 - 3432 of 3432
My worries re the (new) Management are not too grave. They have steered us through a difficult period and it is a real testament to them they did so without resorting to needless and endless dilution. They cut salaries to the bone and have substantially improved the working capital position.
Strategically they seem to have done the right things by bringing in old licences which were not being commercially exploited so they now give us a second chance of trying to exploit in what is a vastly different market. I believe the breast implant market alone will be a huge opportunity.
Meanwhile the enthusiasm of Biomerics towards marketing the existing IP in their field is very impressive and provides serious underpinning to the investment case by itself.
I don't think it will take long for the market to cotton on to the beauty and quality of the model and earnings stream here and once it does I expect AorTech to gain a premium valuation. Many royalty type companies tend to trade on c.33-50x Price Earnings Ratios (2-3% yield). (Quite easy to justify given long term interest rates are 3% whilst with this you have a potential dividend income with growth (and some RPI/CPI inflator built in one would presume))
So assuming they are currently doing c.$300k profits a year put that on 50x you get $15m. And there is nothing in it for the blue sky potential from the additional licensing opportunities. This will be one of the easiest 10 baggers around (and that is just the start IMO)
parsons4 16 Dec '17 - 13:21 - 3431 of 3432
I am relatively new to this one and bought my first holding a few days ago. I think it was TS that mentioned it on the VRS site !! thanks for that. It seems that the company have good products but has been terribly run by previous management for many years. It seems that if there was anything to go wrong it did !!!! But the potential if they now get it right considering the market cap is huge. Have we now got the right management and is Bill Brown any good considering that he has been there for years ?
The Stigologist 16 Dec '17 - 13:58 - 3432 of 3432
My worries re the (new) Management are not too grave. They have steered us through a difficult period and it is a real testament to them they did so without resorting to needless and endless dilution. They cut salaries to the bone and have substantially improved the working capital position.
Strategically they seem to have done the right things by bringing in old licences which were not being commercially exploited so they now give us a second chance of trying to exploit in what is a vastly different market. I believe the breast implant market alone will be a huge opportunity.
Meanwhile the enthusiasm of Biomerics towards marketing the existing IP in their field is very impressive and provides serious underpinning to the investment case by itself.
I don't think it will take long for the market to cotton on to the beauty and quality of the model and earnings stream here and once it does I expect AorTech to gain a premium valuation. Many royalty type companies tend to trade on c.33-50x Price Earnings Ratios (2-3% yield). (Quite easy to justify given long term interest rates are 3% whilst with this you have a potential dividend income with growth (and some RPI/CPI inflator built in one would presume))
So assuming they are currently doing c.$300k profits a year put that on 50x you get $15m. And there is nothing in it for the blue sky potential from the additional licensing opportunities. This will be one of the easiest 10 baggers around (and that is just the start IMO)
ALBA
Good set-up with break of Moving Averages and medium term downtrend on volume
Only technical reservations are MACD still below 0/par line (although it is turning up) and significant resistance levels at 0.5p and 0.7p
Could easily break those on good news though given fundamental value is meant to be multiples of current value
Good set-up with break of Moving Averages and medium term downtrend on volume
Only technical reservations are MACD still below 0/par line (although it is turning up) and significant resistance levels at 0.5p and 0.7p
Could easily break those on good news though given fundamental value is meant to be multiples of current value
Over the years, AorTech has made substantial investment in the development of bio stable polymers and medical device designs. The objective is to capitalise on this investment for the benefit of shareholders...
Significant funding has been achieved by AorTech licencees in developing and commercialising their products with AorTech's Elast-Eon™ seen as critical to their success. In one instance, funds in excess of $100 million have been raised to achieve successful commercialisation. We anticipate that with the renewed interest in our material being generated through our licencing partner, Biomerics, that additional licences may be completed during the course of the next twelve months.
Read more at http://www.pakpassion.net/ppforum/showthread.php?107390-Buying-shares/page83#hckQEi07Lta0iYCD.99
VAL
After a long long time of being pathetic they seem to be delivering
"We are entering a new and very exciting phase, which should result in the crystallisation of substantial value".
ENHANCEMENT OF THE VAL201 DOSE ESCALATION CLINICAL STUDY
"Approval received from the UK Medicines and Healthcare Products Regulatory Agency ("MHRA")
and the Research Ethics Committee ("REC")"
https://www.investegate.co.uk/valirx-plc--val-/rns/re--val201-clinical-trials/201712180700035685Z/
After a long long time of being pathetic they seem to be delivering
"We are entering a new and very exciting phase, which should result in the crystallisation of substantial value".
ENHANCEMENT OF THE VAL201 DOSE ESCALATION CLINICAL STUDY
"Approval received from the UK Medicines and Healthcare Products Regulatory Agency ("MHRA")
and the Research Ethics Committee ("REC")"
https://www.investegate.co.uk/valirx-plc--val-/rns/re--val201-clinical-trials/201712180700035685Z/
GUN
I am selling this stock today.
They have bought shares in an alcohol company.
https://www.investegate.co.uk/gunsynd-plc--gun-/rns/investment-in-human-brands/201712180900016148Z/
I am selling this stock today.
They have bought shares in an alcohol company.
https://www.investegate.co.uk/gunsynd-plc--gun-/rns/investment-in-human-brands/201712180900016148Z/
CPX - optional shares granted to directors, employees
https://www.investegate.co.uk/cap-xx-limited/rns/grant-of-share-options/201712181142426487Z/
https://www.investegate.co.uk/cap-xx-limited/rns/grant-of-share-options/201712181142426487Z/
BMV - interesting offer from Management
https://www.investegate.co.uk/bluebird-merchant--bmv-/rns/funding-update/201712190700037025Z/
Colin Patterson, CEO, commented:
"I strongly believe in both the potential and value of the Gubong project in South Korea as has been demonstrated by my personal commitment and that of the Board and management of Bluebird. We have a highly experienced team who have re-opened mines in various parts of the world and the Gubong project excites me, equally, if not more so, than previous projects that I have undertaken."
"I am convinced that we will create value for shareholders. To demonstrate my confidence I have offered to the Board to personally fund up to USD 700,000 in order to see the project through to the formation of the Joint Venture at Gubong, which is the pre-construction stage and in addition to fund a second exciting project in South Korea that we are considering through to the formation of a Joint Venture and pre-construction stage. As such I remain confident with regards to the financial future of the Company as well as in the value and enormous potential of the Gubong project."
https://www.investegate.co.uk/bluebird-merchant--bmv-/rns/funding-update/201712190700037025Z/
Colin Patterson, CEO, commented:
"I strongly believe in both the potential and value of the Gubong project in South Korea as has been demonstrated by my personal commitment and that of the Board and management of Bluebird. We have a highly experienced team who have re-opened mines in various parts of the world and the Gubong project excites me, equally, if not more so, than previous projects that I have undertaken."
"I am convinced that we will create value for shareholders. To demonstrate my confidence I have offered to the Board to personally fund up to USD 700,000 in order to see the project through to the formation of the Joint Venture at Gubong, which is the pre-construction stage and in addition to fund a second exciting project in South Korea that we are considering through to the formation of a Joint Venture and pre-construction stage. As such I remain confident with regards to the financial future of the Company as well as in the value and enormous potential of the Gubong project."
I am in top up mode on AOR. Very comfortable with the story and think it's multiples undervalued. Very much the same feeling I had with PYC/VAL etc before their recent moves. If anything AOR is better as it's already profitable, cash generative and won't have any placing issues. (any placing will be for good reasons not just to pay Management salaries etc). I am getting close to 3% position.
Align Research done good summary on PFP. They own 3%.
http://www.alignresearch.co.uk/path...-offering-rare-asymmetric-riskreward-profile/
http://www.alignresearch.co.uk/path...-offering-rare-asymmetric-riskreward-profile/
Also Align include PFP in their tips for 2018
http://www.alignresearch.co.uk/equities/align-researchs-top-10-conviction-picks-for-2018/
Pathfinder Minerals – 1.075p
Our next pick is a binary play. If a deal is done with General Veloso then the shares will likely increased five fold overnight (dependent of course upon such deal terms finer details). If there is no deal then the company most likely will become a shell and another opportunity reversed into it. From a risk/reward basis it looks to us that at 1.1p there is perhaps 10 – 20% downside ref a shell value and upwards of 5, 10 times on an immediate reaction basis to a licence resolution deal and very likely much, much more if the large resources of ilmenite, rutile and zircon are ultimately mined. HERE is our indepth commentary as to why we see value and how we see it playing out.
The raising of capital by the company in early December and the recent commentary of a framework deal in place leads us to believe that the odd of news in this regards being released in early 2018 are shortening by the day. In illustrating our conviction in this call we hold just over 3% of the company.
http://www.alignresearch.co.uk/equities/align-researchs-top-10-conviction-picks-for-2018/
Pathfinder Minerals – 1.075p
Our next pick is a binary play. If a deal is done with General Veloso then the shares will likely increased five fold overnight (dependent of course upon such deal terms finer details). If there is no deal then the company most likely will become a shell and another opportunity reversed into it. From a risk/reward basis it looks to us that at 1.1p there is perhaps 10 – 20% downside ref a shell value and upwards of 5, 10 times on an immediate reaction basis to a licence resolution deal and very likely much, much more if the large resources of ilmenite, rutile and zircon are ultimately mined. HERE is our indepth commentary as to why we see value and how we see it playing out.
The raising of capital by the company in early December and the recent commentary of a framework deal in place leads us to believe that the odd of news in this regards being released in early 2018 are shortening by the day. In illustrating our conviction in this call we hold just over 3% of the company.
<blockquote class="twitter-tweet"><p lang="en" dir="ltr">Copper prices climb to highest level in 4 years <a href="https://t.co/YstICxgXbj">https://t.co/YstICxgXbj</a></p>— Financial Times (@FT) <a href="https://twitter.com/FT/status/946060231574020097?ref_src=twsrc%5Etfw">December 27, 2017</a></blockquote> <script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
AOR
cocker 28 Dec '17 - 11:06 - 3479 of 3479
Interesting times ahead?
1) Obviously the settlement has a clause within it. Surely this will be exposed during the next set of results as an exceptional(perhaps some of you guys may have a take on this).
2) The CEO has said that the court case has enlightened them to the possibilities of their intellectual property. This if exploited may seriously send the sp into orbit.
3) The tax losses within the accounts also makes AOR attractive to a prospective buyer, as with millions to play with this could well prove to tempting to a profit making organisation.
Happy new year & lets hope AOR finally rewards some of us.
cocker 28 Dec '17 - 11:06 - 3479 of 3479
Interesting times ahead?
1) Obviously the settlement has a clause within it. Surely this will be exposed during the next set of results as an exceptional(perhaps some of you guys may have a take on this).
2) The CEO has said that the court case has enlightened them to the possibilities of their intellectual property. This if exploited may seriously send the sp into orbit.
3) The tax losses within the accounts also makes AOR attractive to a prospective buyer, as with millions to play with this could well prove to tempting to a profit making organisation.
Happy new year & lets hope AOR finally rewards some of us.
RRR Align Research note
https://www.investegate.co.uk/red-r...arch-coverage-initiation/201801030715017797A/
https://www.investegate.co.uk/red-r...arch-coverage-initiation/201801030715017797A/
AOR some snippets from historic result statements highlighting the value AOR tech provides to licensees
Co- Development Project - $32 million
In July 2007, we announced a licensing and supply agreement for the evaluation of Elast-Eon™ by a global device company. This agreement allowed the licensee to acquire certain AorTech intellectual property rights and encompassed potential milestone payments of up to $32 million. The Agreement between AorTech and the licensee has recently been terminated by mutual consent with AorTech re-acquiring all of its Patents and it's Intellectual Property at the end of the notice period on 1 March 2012. Your Board believes that it is in the long term interests of the Company and its shareholders to take ownership of this Intellectual Property which is one of the key drivers to creating shareholder value. Later in this report I will explain the Group's strategy to benefit fully from the value of AorTech's Intellectual Property.
St Jude Medical - Pacing Leads
Shareholders may well be aware of the success St Jude Medical ('SJM') is achieving in the Cardiac Rhythm Management market by having converted the insulation of all of their pacing products to Elast-Eon™ (re-branded by St Jude as Optim™). A recent Credit Suisse note on SJM (8 November 2011) increased the target valuation of St Jude by $1.6 billion due to the success of the durability performance of Optim™ insulated leads. We view this development as very positive as it demonstrates to not only the medical device industry but also the financial markets the value that can be added to a medical device by utilising AorTech's Elast-Eon™ material, and this provides a significant marketing opportunity for us.
Co- Development Project - $32 million
In July 2007, we announced a licensing and supply agreement for the evaluation of Elast-Eon™ by a global device company. This agreement allowed the licensee to acquire certain AorTech intellectual property rights and encompassed potential milestone payments of up to $32 million. The Agreement between AorTech and the licensee has recently been terminated by mutual consent with AorTech re-acquiring all of its Patents and it's Intellectual Property at the end of the notice period on 1 March 2012. Your Board believes that it is in the long term interests of the Company and its shareholders to take ownership of this Intellectual Property which is one of the key drivers to creating shareholder value. Later in this report I will explain the Group's strategy to benefit fully from the value of AorTech's Intellectual Property.
St Jude Medical - Pacing Leads
Shareholders may well be aware of the success St Jude Medical ('SJM') is achieving in the Cardiac Rhythm Management market by having converted the insulation of all of their pacing products to Elast-Eon™ (re-branded by St Jude as Optim™). A recent Credit Suisse note on SJM (8 November 2011) increased the target valuation of St Jude by $1.6 billion due to the success of the durability performance of Optim™ insulated leads. We view this development as very positive as it demonstrates to not only the medical device industry but also the financial markets the value that can be added to a medical device by utilising AorTech's Elast-Eon™ material, and this provides a significant marketing opportunity for us.
VRS Major entry into China and with high profile Chinese Government partnerships by looks of it
https://www.investegate.co.uk/versa...e-manufacturing-facility/201801150700048078B/
https://www.investegate.co.uk/versa...e-manufacturing-facility/201801150700048078B/
RRR expect retest of former resistance as support (on lower volume and thus textbook consolidation) before next move up
Pretty good guess as it turned out. (Recent news stories putting EBITDA at c.$170m)
With current Manganese price at $6/dmtu the cashflow numbers get a bit silly
AXM Not sure what this AXM RNS was meant to achieve
Loads of verbiage about yet another early stage leaching trial (this time for Nickel and Cobalt) only likely to bear some fruit in the medium term... followed by an admission there have been further 'procedural delays' to the Lithium processing results
Frustrating but the upside potential remains huge and it's linked with some crucial strategic metals in a bull market for them so sticking with it as it bumps along the bottom. Seems very good asymmetric payoff potential.
https://www.investegate.co.uk/alexa...h-and-development-update/201801240756577628C/
Loads of verbiage about yet another early stage leaching trial (this time for Nickel and Cobalt) only likely to bear some fruit in the medium term... followed by an admission there have been further 'procedural delays' to the Lithium processing results
Frustrating but the upside potential remains huge and it's linked with some crucial strategic metals in a bull market for them so sticking with it as it bumps along the bottom. Seems very good asymmetric payoff potential.
https://www.investegate.co.uk/alexa...h-and-development-update/201801240756577628C/
BlueDoritos
Tape Ball Star
- Joined
- Jan 8, 2018
- Runs
- 936
The Pakistan Stock Exchange (PSX) registered nominal gains on Wednesday following another volatile session, with the benchmark KSE-100 index gaining 156 points to close above 45,000 level.
The index opened higher and touched the day's high of 45,495 points before facing a mid-session fall which brought the index to 44,782 points before it managed to close at 45,063.
All share volumes increased by 114 million shares from Tuesday to around 340 million shares today. The traded value also climbed to Rs18.2 billion from Rs13.3 billion a day earlier.
Of the total of 374 traded scrips, 215 advanced and 139 declined while 2 remained unchanged.
The cement sector dominated trading for the third session in a row with 58.6 million shares traded while technology and communication followed with 46.4m shares traded.
https://www.suchtv.pk/business/item/65325-pakistan-stock-exchange-continues-positive-run.html
The index opened higher and touched the day's high of 45,495 points before facing a mid-session fall which brought the index to 44,782 points before it managed to close at 45,063.
All share volumes increased by 114 million shares from Tuesday to around 340 million shares today. The traded value also climbed to Rs18.2 billion from Rs13.3 billion a day earlier.
Of the total of 374 traded scrips, 215 advanced and 139 declined while 2 remained unchanged.
The cement sector dominated trading for the third session in a row with 58.6 million shares traded while technology and communication followed with 46.4m shares traded.
https://www.suchtv.pk/business/item/65325-pakistan-stock-exchange-continues-positive-run.html
BlueDoritos
Tape Ball Star
- Joined
- Jan 8, 2018
- Runs
- 936
Oil and Gas Development Company Limited (OGDCL) has made a second discovery of oil and gas deposits at the Baratai Block in Khyber-Pakhtunkhwa (K-P), stated a stock exchange notice sent on Tuesday.
The state-owned firm, which remains the single largest oil exploration company listed at the Pakistan Stock Exchange (PSX), said in a notification to the bourse that it has tested 13.56 million standard cubic feet per day (mmscfd) of gas and 317 barrels per day (bpd) of condensate (crude oil) at a zone in Lockhart formation in the last week of December.
OGDCL’s share price increased 1.31% or Rs2.25 to close at Rs173.84 with 1.77 million shares changing hands at the PSX.
Earlier in mid-December, OGDCL – the operator of the joint venture of Baratai Block in the province with 97.5% stake – drilled the exploratory well Dhok Hussain well #01 to the depth of 5,014 meters and tested hydrocarbons.
“The well has tested 15.40mmscfd of gas and 360 barrels per day of condensate,” Company Secretary Zafar Ahmad said in the notification. Khyber Pakhunkhwa Oil and Gas Company Limited (KPOGCL) holds the remaining 2.5% stake in the joint venture.
The structure of the well was drilled and tested using OGDCL’s in-house expertise, the operator underlined.
“The discovery of Dhok Hussain well #01 is a result of aggressive exploration strategy adopted by the company. It has opened new avenues and would add to the hydrocarbon reserves base of OGDC and the country,” he said.
Domestic production meets around 30% needs for oil and around 70% for gas in the country. The rest is met through imports.
Taurus Securities said in a post-discovery note that on the additional flows mentioned, the company will have a positive annualised impact of Rs0.29 per share assuming $55 barrels per day oil price and Pakistani currency at Rs110 for the US dollar.
On a cumulative basis, annualised impact from Dhok Hussian works out to be Rs0.61 per share, which is 4.1% of earnings per share in the fiscal year 2017, it said.
https://tribune.com.pk/story/1616372/2-ogdcl-makes-second-discovery-oil-gas-khyber-pakhtunkhwa/
The state-owned firm, which remains the single largest oil exploration company listed at the Pakistan Stock Exchange (PSX), said in a notification to the bourse that it has tested 13.56 million standard cubic feet per day (mmscfd) of gas and 317 barrels per day (bpd) of condensate (crude oil) at a zone in Lockhart formation in the last week of December.
OGDCL’s share price increased 1.31% or Rs2.25 to close at Rs173.84 with 1.77 million shares changing hands at the PSX.
Earlier in mid-December, OGDCL – the operator of the joint venture of Baratai Block in the province with 97.5% stake – drilled the exploratory well Dhok Hussain well #01 to the depth of 5,014 meters and tested hydrocarbons.
“The well has tested 15.40mmscfd of gas and 360 barrels per day of condensate,” Company Secretary Zafar Ahmad said in the notification. Khyber Pakhunkhwa Oil and Gas Company Limited (KPOGCL) holds the remaining 2.5% stake in the joint venture.
The structure of the well was drilled and tested using OGDCL’s in-house expertise, the operator underlined.
“The discovery of Dhok Hussain well #01 is a result of aggressive exploration strategy adopted by the company. It has opened new avenues and would add to the hydrocarbon reserves base of OGDC and the country,” he said.
Domestic production meets around 30% needs for oil and around 70% for gas in the country. The rest is met through imports.
Taurus Securities said in a post-discovery note that on the additional flows mentioned, the company will have a positive annualised impact of Rs0.29 per share assuming $55 barrels per day oil price and Pakistani currency at Rs110 for the US dollar.
On a cumulative basis, annualised impact from Dhok Hussian works out to be Rs0.61 per share, which is 4.1% of earnings per share in the fiscal year 2017, it said.
https://tribune.com.pk/story/1616372/2-ogdcl-makes-second-discovery-oil-gas-khyber-pakhtunkhwa/
VRS new all time highs off the back of news that they will be going to China with Theresa May to complete some massive deals
<blockquote class="twitter-tweet" data-lang="en-gb"><p lang="en" dir="ltr">Exclusive: Downing Street races to finalise dozens of corporate deals ahead of Theresa May’s trip to China next week. I’ve obtained the list of companies travelling with her. <a href="https://t.co/yfnsnrHvQL">https://t.co/yfnsnrHvQL</a></p>— Mark Kleinman (@MarkKleinmanSky) <a href="https://twitter.com/MarkKleinmanSky/status/956847351112589312?ref_src=twsrc%5Etfw">26 January 2018</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
<blockquote class="twitter-tweet" data-lang="en-gb"><p lang="en" dir="ltr">Exclusive: Downing Street races to finalise dozens of corporate deals ahead of Theresa May’s trip to China next week. I’ve obtained the list of companies travelling with her. <a href="https://t.co/yfnsnrHvQL">https://t.co/yfnsnrHvQL</a></p>— Mark Kleinman (@MarkKleinmanSky) <a href="https://twitter.com/MarkKleinmanSky/status/956847351112589312?ref_src=twsrc%5Etfw">26 January 2018</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>
AOR
The Stigologist 28 Jan '18 - 12:32 - 3651 of 3652
The potential here is incredible... start delivering on some of these and we should see 100p as a starting point for any rise
Outlook/Conclusion (from August 15th Final Results RNS)
"A new revenue-generating licence has been signed and enquiries have increased markedly. We have taken back control of our breast implant IP and are actively pursuing opportunities to exploit this alongside our other intellectual property, including heart valves and polymers."
The Stigologist 28 Jan '18 - 12:32 - 3651 of 3652
The potential here is incredible... start delivering on some of these and we should see 100p as a starting point for any rise
Outlook/Conclusion (from August 15th Final Results RNS)
"A new revenue-generating licence has been signed and enquiries have increased markedly. We have taken back control of our breast implant IP and are actively pursuing opportunities to exploit this alongside our other intellectual property, including heart valves and polymers."
Good spot. I hadn't seen that.
Can't honestly say whether it is good or not. Just good to see there is a pulse. Have a small position to monitor because it strikes me as one on the right news could go up 5-10x just for a start
Martin Rosser, Chief Executive Officer, said: "The technology described in the patent has significant potential application in Canada, both for sulphide deposits and for converting sulphide concentrates, the source of the majority of the world's base metals production and resources, through to metal at the mine site."
https://www.investegate.co.uk/alexa...patent-granted-in-canada/201801291158292140D/
Can't honestly say whether it is good or not. Just good to see there is a pulse. Have a small position to monitor because it strikes me as one on the right news could go up 5-10x just for a start
Martin Rosser, Chief Executive Officer, said: "The technology described in the patent has significant potential application in Canada, both for sulphide deposits and for converting sulphide concentrates, the source of the majority of the world's base metals production and resources, through to metal at the mine site."
https://www.investegate.co.uk/alexa...patent-granted-in-canada/201801291158292140D/
So the basics on this are that they developed this Elast-eon technology about 17 years ago. Failed to become a device manufacturer themselves. Licensed the materials tech unsuccessfully initially and on bad terms to much bigger players. Got into loads of litigation to try to protect their Intellectual Property etc. Finally seem to have drawn a line under previous litigation and found a licensing partner Biomerics who is delivering. Reckon that having learnt from previous experiences they can licence their tech successfully for some other devices e.g. Breast implants and Heart Valves. Their current valuation is totally out of sync with what even Private Start-ups are valued at (e.g. Edwards buying Harpoon a couple of weeks ago for $100-250m) which don't have the track record of successful clinical use or FDA approvals.
AOR AorTech
Share Price : 50p
Market Cap : £2.8m
AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.
Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.
Valuation comparitors :-
Major licensee is Biomerics. Private Company. Recently spent $38m on a HQ building alone.
http://biomerics.com/elast-eon-bringing-quality-value-medical-device-project/
Edwards Lifesciences bought Harpoon Medical for $100-250m (December 6th 2017) http://www.edwards.com/ns20171206
"The HARPOON system is designed to facilitate echo-guided repair of mitral valve regurgitation, by stabilizing the prolapsed mitral valve leaflet to restore proper coaptation and valve function"
Xeltis achieved largest private equity funding round for a medical device in Europe of $52m in 2017 (November 15th 2017)
http://www.xeltis.com/news/xeltis-closes-e45-million-series-c-financing/
AorTech comments :-
General licenses :- "Significant funding has been achieved by AorTech licencees in developing and commercialising their products with AorTech's Elast-Eon™ seen as critical to their success. In one instance, funds in excess of $100 million have been raised to achieve successful commercialisation."
On their Heart Valve Project :-
"We have previously announced a potential transaction with a new business established to commercialise the AorTech heart valve technology. Fund raising for the new project is continuing but is not yet finalised and any license will be dependent upon the new business being fully funded. The package of data and information that AorTech is able to deliver to the project is substantial. This ranges from specific manufacturing know how and trade secrets for the precise polymer best suited to a heart valve, detailed design files for a polymer valve with a stress/strain profile substantially less than the material mechanical properties, together with a fully documented manufacturing process that allows a clinical quality valve to be made on a repeatable basis. All of these processes have been developed over a number of years of trial and error and experimentation at considerable investment by AorTech."
AOR AorTech
Share Price : 50p
Market Cap : £2.8m
AorTech has developed biostable, implantable polymers, including Elast-Eon™ and ECSil™ the world's leading long-term implantable co-polymers, now manufactured on their behalf by Biomerics LLC in Utah, USA. With several million implants and seven years of successful clinical use, AorTech polymers are being developed and used in cardiology and urological applications, including pacing leads, cardiac cannulae, stents and neuro stimulation devices. Devices manufactured from AorTech polymers have numerous US FDA PMA approvals, 510k's, CE Marks, Australian TGA and Japanese Ministry of Health approvals.
Elast-Eon™ and ECSil™'s biostability is comparable to silicone while exhibiting excellent mechanical, blood contacting and flex-fatigue properties. These polymers can be processed using conventional thermoplastic extrusion and moulding techniques. A range of materials in a variety of application-specific formulations for use in medical devices and components are available.
Valuation comparitors :-
Major licensee is Biomerics. Private Company. Recently spent $38m on a HQ building alone.
http://biomerics.com/elast-eon-bringing-quality-value-medical-device-project/
Edwards Lifesciences bought Harpoon Medical for $100-250m (December 6th 2017) http://www.edwards.com/ns20171206
"The HARPOON system is designed to facilitate echo-guided repair of mitral valve regurgitation, by stabilizing the prolapsed mitral valve leaflet to restore proper coaptation and valve function"
Xeltis achieved largest private equity funding round for a medical device in Europe of $52m in 2017 (November 15th 2017)
http://www.xeltis.com/news/xeltis-closes-e45-million-series-c-financing/
AorTech comments :-
General licenses :- "Significant funding has been achieved by AorTech licencees in developing and commercialising their products with AorTech's Elast-Eon™ seen as critical to their success. In one instance, funds in excess of $100 million have been raised to achieve successful commercialisation."
On their Heart Valve Project :-
"We have previously announced a potential transaction with a new business established to commercialise the AorTech heart valve technology. Fund raising for the new project is continuing but is not yet finalised and any license will be dependent upon the new business being fully funded. The package of data and information that AorTech is able to deliver to the project is substantial. This ranges from specific manufacturing know how and trade secrets for the precise polymer best suited to a heart valve, detailed design files for a polymer valve with a stress/strain profile substantially less than the material mechanical properties, together with a fully documented manufacturing process that allows a clinical quality valve to be made on a repeatable basis. All of these processes have been developed over a number of years of trial and error and experimentation at considerable investment by AorTech."
AXM progressing on multiple fronts, this one is a bit of a sideshow compared to potential re Copper, Cobalt, Lithium
https://www.investegate.co.uk/alexander-mining-plc--axm-/rns/project-update/201801310942474684D/
https://www.investegate.co.uk/alexander-mining-plc--axm-/rns/project-update/201801310942474684D/
AssassinatedDevil
Local Club Star
- Joined
- Nov 6, 2017
- Runs
- 2,035
- Post of the Week
- 1
Any NASDAQ or NYSE traders here? Who's hyped for ER season?
Mr.Q
Tape Ball Star
- Joined
- Dec 2, 2017
- Runs
- 875
- Post of the Week
- 1
India has introduced capital gains tax of 10% on financial assets. Gains above 1lakh will be taxed. I'm a bit disappointed as an investor but this was needed as those fund houses have been getting away with huge profits without contributing to the nation's development.
Dow Jones and S.&P. Slide Again, Dropping by More Than 4%
Since the global financial crisis a decade ago, a few simple guidelines have helped investors make sense of the markets.
Global growth and inflation will be perpetually weak. Central banks will help by keeping interest rates low. And stocks will almost invariably rise.
The rule book is now changing, a shift that is sending tremors through the financial markets. The Standard & Poor’s 500-stock index fell by more than 4 percent on Monday, deepening its losses from the previous week and erasing its gains for the year. The Dow Jones industrial average sank by 4.6 percent. Bond yields, the basis for key borrowing costs such as mortgage rates, have risen fast in recent weeks.
In trading in Asia on Tuesday morning, markets signaled another tough day. Major stock markets in the region plunged after the drop in the United States on Monday, suggesting the pain could continue. In Japan, stocks were down more than 5 percent in morning trading, while shares in Hong Kong were down more than 4 percent.
Those sharp moves come as investors digest the growth prospects for the world — and rebalance their views on the relative merits of stashing their cash in risky assets like stocks, safer spots such as government bonds and the myriad investment opportunities offered by a global economy moving in sync.
The world’s largest economies are all expanding, as the most important central bank, the United States Federal Reserve, is draining billions of dollars from the financial system and raising interest rates. And investors are concerned that tenuous signs of inflation could mean central banks around the world will start to remove their support even faster.
It’s an interesting complexity for investors to assess. What’s good for the economy isn’t always good for the markets. The strong job report last week fueled hopes that wage growth would follow. But higher wages could lead to higher inflation, creating new challenges for the central bank to manage.
New leadership at the Fed is adding a degree of uncertainty. Jerome H. Powell was sworn in as the 16th chairman of the Federal Reserve on Monday, after the departure of his predecessor, Janet L. Yellen. The markets do not have a clear understanding of exactly how, if at all, Mr. Powell’s views on unemployment and inflation will differ from that of Ms. Yellen.
A rocky patch for the markets could become awkward for President Trump. He has repeatedly claimed credit for surging stocks, while business optimism over his push to cut taxes and decrease regulation has helped fuel the “Trump Bump.”
While giving a speech during Monday’s sell-off, Mr. Trump made no mention of stocks. Afterward, the White House instead extolled the “long-term economic fundamentals, which remain exceptionally strong, with strengthening U.S. economic growth, historically low unemployment, and increasing wages for American workers.”
Mr. Trump’s habit of regularly boasting about stock market surges is a practice other presidents avoided. They knew that what goes up may go down again, and they did not want to take the blame for market forces beyond their control.
https://mobile.nytimes.com/2018/02/...rkets.html?referer=https://www.google.com.bh/
Since the global financial crisis a decade ago, a few simple guidelines have helped investors make sense of the markets.
Global growth and inflation will be perpetually weak. Central banks will help by keeping interest rates low. And stocks will almost invariably rise.
The rule book is now changing, a shift that is sending tremors through the financial markets. The Standard & Poor’s 500-stock index fell by more than 4 percent on Monday, deepening its losses from the previous week and erasing its gains for the year. The Dow Jones industrial average sank by 4.6 percent. Bond yields, the basis for key borrowing costs such as mortgage rates, have risen fast in recent weeks.
In trading in Asia on Tuesday morning, markets signaled another tough day. Major stock markets in the region plunged after the drop in the United States on Monday, suggesting the pain could continue. In Japan, stocks were down more than 5 percent in morning trading, while shares in Hong Kong were down more than 4 percent.
Those sharp moves come as investors digest the growth prospects for the world — and rebalance their views on the relative merits of stashing their cash in risky assets like stocks, safer spots such as government bonds and the myriad investment opportunities offered by a global economy moving in sync.
The world’s largest economies are all expanding, as the most important central bank, the United States Federal Reserve, is draining billions of dollars from the financial system and raising interest rates. And investors are concerned that tenuous signs of inflation could mean central banks around the world will start to remove their support even faster.
It’s an interesting complexity for investors to assess. What’s good for the economy isn’t always good for the markets. The strong job report last week fueled hopes that wage growth would follow. But higher wages could lead to higher inflation, creating new challenges for the central bank to manage.
New leadership at the Fed is adding a degree of uncertainty. Jerome H. Powell was sworn in as the 16th chairman of the Federal Reserve on Monday, after the departure of his predecessor, Janet L. Yellen. The markets do not have a clear understanding of exactly how, if at all, Mr. Powell’s views on unemployment and inflation will differ from that of Ms. Yellen.
A rocky patch for the markets could become awkward for President Trump. He has repeatedly claimed credit for surging stocks, while business optimism over his push to cut taxes and decrease regulation has helped fuel the “Trump Bump.”
While giving a speech during Monday’s sell-off, Mr. Trump made no mention of stocks. Afterward, the White House instead extolled the “long-term economic fundamentals, which remain exceptionally strong, with strengthening U.S. economic growth, historically low unemployment, and increasing wages for American workers.”
Mr. Trump’s habit of regularly boasting about stock market surges is a practice other presidents avoided. They knew that what goes up may go down again, and they did not want to take the blame for market forces beyond their control.
https://mobile.nytimes.com/2018/02/...rkets.html?referer=https://www.google.com.bh/
Mr.Q
Tape Ball Star
- Joined
- Dec 2, 2017
- Runs
- 875
- Post of the Week
- 1
No reactions here after such a steep fall? I had positions open overnight. It was horrendous 
- Joined
- Oct 2, 2004
- Runs
- 217,749
No reactions here after such a steep fall? I had positions open overnight. It was horrendous
Things can only improve!
R3verse Swing
Local Club Star
- Joined
- Jan 8, 2018
- Runs
- 2,163
You have to laugh at the state of the economy.
Index tanked 10% on GOOD NEWS in USA on Friday.
Index tanked 10% on GOOD NEWS in USA on Friday.
Mr.Q
Tape Ball Star
- Joined
- Dec 2, 2017
- Runs
- 875
- Post of the Week
- 1
Yeah. But that strange feeling when you realise stop loss has been triggered on all positions before you could do anything
.Btw, is it possible for an Indian/NRI to invest in the Pakistan stock market? I heard the returns have been huge compared to most other markets.
Mr.Q
Tape Ball Star
- Joined
- Dec 2, 2017
- Runs
- 875
- Post of the Week
- 1
This is bad. Dow sinks again!
VAL
recent Investor presentation slides following some successful PhaseI/PhaseII trial results
http://s1.moneyam.com/pdfs/20180213-investor-evening/valirx.pdf
recent Investor presentation slides following some successful PhaseI/PhaseII trial results
http://s1.moneyam.com/pdfs/20180213-investor-evening/valirx.pdf
Majestic_Inzi
First Class Star
- Joined
- Feb 9, 2007
- Runs
- 3,970
RRR
expecting a return of loan from steelmin by next wed, will positively increase bank balance of rrr of £1.8m, Jupiter share we own £364k dividends/buyback expected next month, RRR holds 1.2% of jupiters mines, planned ipo in ASX next month or early april, our share valued between £6m-£9m, receiving loan repayment from el-limon on 1st april $750k.
Currently negotiating to get back our migori gold license which holds 1.2Moz Au jorc reserve.
Signing Cobalt deal next month.
all for a mkt cap of 4.7m, multibagger on cards.
expecting a return of loan from steelmin by next wed, will positively increase bank balance of rrr of £1.8m, Jupiter share we own £364k dividends/buyback expected next month, RRR holds 1.2% of jupiters mines, planned ipo in ASX next month or early april, our share valued between £6m-£9m, receiving loan repayment from el-limon on 1st april $750k.
Currently negotiating to get back our migori gold license which holds 1.2Moz Au jorc reserve.
Signing Cobalt deal next month.
all for a mkt cap of 4.7m, multibagger on cards.
Majestic_Inzi
First Class Star
- Joined
- Feb 9, 2007
- Runs
- 3,970
I think there is uncertainty on the Steelmin payment. IF they get it yes all systems go for this stock.
JMS is going to be raking in cash given current Manganese price
Well we will know by next wed as that is the date when they will have to extend the loan as per the terms. Interesting times...
PYC after a 1p to 32p move in Q4 2017 has had a decent retrace but the newsflow if anything is strengthening
what's really interesting is that they went to JP Morgan Biotech Showcase in Jan 2018 for 1-on-1 meetings with several companies, and have come back saying 'the halo effect of recent announcements has led to a significant expansion of our business development pipeline amongst both small and large potential clients'
what's really interesting is that they went to JP Morgan Biotech Showcase in Jan 2018 for 1-on-1 meetings with several companies, and have come back saying 'the halo effect of recent announcements has led to a significant expansion of our business development pipeline amongst both small and large potential clients'
CPX Interim Results out
As we've come to expect still 'jam tomorrow'. I think the good sign is the royalty income growth and eventually would expect this to be rated very highly so I think stock underpinned at around 10p with little account for the potential upside optionality
https://www.investegate.co.uk/cap-xx-limited--cpx-/rns/interim-results/201803060700057661G/
As we've come to expect still 'jam tomorrow'. I think the good sign is the royalty income growth and eventually would expect this to be rated very highly so I think stock underpinned at around 10p with little account for the potential upside optionality
https://www.investegate.co.uk/cap-xx-limited--cpx-/rns/interim-results/201803060700057661G/
Similar threads
